Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2021

View Archived Issues

Potent selective pan-serotype dengue inhibitor developed

Discovery and preclinical characterization of novel TLR3 agonist, TL-532

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent ADCs including B7-H3 antibodies

New NLRP3 inflammasome inhibitors identified at Astellas Pharma

Atux Iskay presents new anticancer compounds

New TRK inhibitors divulged by J2H Biotech

Preclinical data presented for RP-3500

NVL-520 demonstrates efficacy in PDX models harboring ROS1 fusions

Regeneration of GABAergic neurons by in vivo reprogramming of glial cells reduces epileptic seizures

BRD9 is a druggable target for treating ccRCC with absent or low HIF-2alpha expression

ENPP1 inhibitor TXN-10128 shows promising antitumor activity trough restoration of STING activation

AavantiBio expands partnership with University of Florida to create gene therapy capsids

Creative Medical Technology announces proof-of-concept data on ImmCelz immunotherapy product

Hereditary Neuropathy Foundation and Rarebase partner to find treatments for Charcot-Marie Tooth

Poseida and Takeda partner on nonviral in vivo gene therapy programs

Amydis receives NINDS funding to explore presence of ASYN in retina of Parkinson's models

Kallistatin is a marker of NAFLD progression in patients with hypertension

NV-CoV-2 effective against SARS-CoV-2 in standard cell culture pseudovirion assay

Liver TR-beta1 activation can alleviate nonalcoholic steatohepatitis

NCI grant supports development of ST-316 to treat Wnt/beta-catenin-dependent breast cancer

Preclinical data support use of ibrexafungerp to treat mucormycosis

Emmaus gains license to Kainos' novel IRAK-4 inhibitor KM-10544

BridgeBio reports highlights from preclinical cancer and gene therapy pipelines

Vaxil reports data on P-Esbp-DOX in mouse model of aggressive liver metastasis of colorectal tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...